Table 1. Patient characteristics and integrated profiles in the TCGA PTC cohort.
| Variables | PTC LNN | PTC LNM-P | ||
|---|---|---|---|---|
| N0 (n = 213) | N1 (n = 53) | N1a (n = 86) | N1b (n = 66) | |
| Age range (years) | 15–85 | 19–83 | 18–83 | 19–89 |
| Mean age | 49.4 | 41.9 | 43.5 | 48.4 |
| Gender (n) | ||||
| Male | 50 (23.5%) | 14 (26.4%) | 25 (29.1%) | 27 (40.9%) |
| Female | 163 (76.5%) | 39 (73.6%) | 61 (70.9%) | 39 (59.1%) |
| Disease free status | ||||
| Recurred/progressed | 5 (2.3%) | 7 (13.2%) | 6 (7%) | 6 (9.1%) |
| Disease free | 178 (83.6%) | 41 (77.4%) | 75 (87.2%) | 47 (71.2%) |
| Unknown | 30 (14.1%) | 5 (9.4%) | 5 (5.8%) | 13 (19.7%) |
| Disease free (range in months) | 0.03–155 | 0–131 | 0–157 | 0.2 –46 |
| Mean disease-free survival | 23.6 (n = 183) | 34.5 (n = 48) | 21.5 (n = 81) | 13.5 (n = 53) |
| Overall survival status | ||||
| Deceased | 35 (16.4%) | 12 (22.6%) | 11 (12.8%) | 19 (28.8%) |
| Alive | 178 (83.6%) | 41 (77.6%) | 75 (87.2%) | 47 (71.2%) |
| Overall survival (range in months) | 0.03–155 | 0–131 | 0–157 | 0.2 –97.7 |
| Mean overall survival | 24.3 (n = 182) | 35.2 (n = 43) | 21.4 (n = 75) | 15.2 (n = 50) |
| Extrathyroidal extension | ||||
| None | 160 (75.1%) | 31 (58.5%) | 49 (57%) | 37 (56.1%) |
| Minimal (T3) | 42 (19.7%) | 14 (26.4%) | 33 (38.4%) | 23 (34.8%) |
| Moderate/advanced (T4a) | 3 (1.4%) | 5 (9.4%) | 1 (1.2%) | 4 (6.1%) |
| Very advanced (T4b) | 0 (0%) | 1 (1.9%) | 0 (0%) | 0 (0%) |
| Unknown | 8 (3.8%) | 2 (3.8%) | 3 (3.5%) | 2 (3%) |
| BRAF status | ||||
| Mutated | 94 (44.1%) | 25 (47.2%) | 53 (61.6%) | 32 (48.9%) |
| Wild type | 119 (55.9%) | 28 (52.8%) | 33 (38.4%) | 34 (51.5%) |